ArticleCancer2016
Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies.
Article in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 63 citations in OpenAlex.
- The Complex Path from Mammary Ductal Hyperplasia to Breast Cancer: Elevated Malignancy Risk in Atypical Forms.Biomedicines · 2026Review
- High-Risk Breast Lesions on Core Biopsy: Rates of Upgrade and Management Recommendations.Surgical pathology clinics · 2025Review
- Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England.BMJ (Clinical research ed.) · 2024Observational
- An update on intraductal and intralobular proliferative lesions of the breast.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Article
- Article
- Deep Learning Image Analysis of Benign Breast Disease to Identify Subsequent Risk of Breast Cancer.JNCI cancer spectrum · 2021Article
- Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity?The Journal of surgical research · 2020Article
- Deep learning assessment of breast terminal duct lobular unit involution: Towards automated prediction of breast cancer risk.PloS one · 2020Article
- The Regulatory Role of MicroRNAs in Breast Cancer.International journal of molecular sciences · 2019Review
- The Influence of Age on the Histopathology and Prognosis of Atypical Breast Lesions.The Journal of surgical research · 2019Article
- Diagnostic terminology used to describe atypia on breast core needle biopsy: correlation with excision and upgrade rates.Diagnostic pathology · 2019Article
- Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).Breast cancer research and treatment · 2019Review
- Atypical Ductal Lesions of the Breast: Criteria, Significance, and Laboratory Updates.Archives of pathology & laboratory medicine · 2018Review
- Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape.Breast cancer research : BCR · 2018Review
- Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer.Cancer · 2018Article
- Primed atypical ductal hyperplasia-associated fibroblasts promote cell growth and polarity changes of transformed epithelium-like breast cancer MCF-7 cells via miR-200b/c-IKKβ signaling.Cell death & disease · 2018Article
- 'No Pink Ribbons': How Women's Lived Experiences With Breast Atypia Inform Decisions Involving Risk-Reducing Medications.Journal of patient-centered research and reviews · 2018Article
- Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy.JAMA oncology · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundWomen with atypical hyperplasia (AH) on a benign breast biopsy specimen are at increased risk for the development of breast cancer. However, the relation between the type and extent of AH (atypical ductal hyperplasia [ADH] vs atypical lobular hyperplasia [ALH]) and the magnitude of the breast cancer risk is not well defined.
methodsA nested case-control study of benign breast disease and breast cancer risk was conducted. Women with breast cancer and prior benign breast biopsy findings (488 cases) were matched to women with prior benign breast biopsy findings who were free from breast cancer (1907 controls). Benign breast biopsy slides were reviewed and categorized as nonproliferative, proliferative without atypia, or AH (ADH or ALH). The number of foci of AH was also recorded.
resultsAmong women with ADH, the interrelation between the extent of atypia and breast cancer risk was not significant (odds ratio [OR] for 1 or 2 foci, 3.5; 95% confidence interval [CI], 2.2-5.6; OR for ≥3 foci, 2.7; 95% CI, 1.4-5.1; P = .41). Similarly, although the risk with ALH was higher for those with ≥3 foci than for those with <3 foci, the difference was not statistically significant (OR for 1 or 2 foci, 5.2; 95% CI, 2.7-10.0; OR for ≥3 foci, 8.0; 95% CI, 4.5-14.2; P = .19).
conclusionsThis analysis demonstrates that the extent of ADH or ALH does not significantly contribute to breast cancer risk. The lack of a significant dose-response relation between the extent and type of atypia and breast cancer risk suggests that it would be premature to use the extent of atypia to influence management decisions for women with ADH or ALH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.